These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 8608487)

  • 21. Immunohistochemical study of chromogranin A in Stage D2 prostate cancer.
    Kokubo H; Yamada Y; Nishio Y; Fukatsu H; Honda N; Nakagawa A; Saga S; Tsuzuki T; Hara K
    Urology; 2005 Jul; 66(1):135-40. PubMed ID: 15992907
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Decreased immunostaining for macrophage scavenger receptor is associated with poor prognosis of prostate cancer.
    Takayama H; Nonomura N; Nishimura K; Oka D; Shiba M; Nakai Y; Nakayama M; Tsujimura A; Aozasa K; Okuyama A
    BJU Int; 2009 Feb; 103(4):470-4. PubMed ID: 18778349
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Correlation between re-biopsy one year after endocrine therapy and long-term prognosis in localized prostate cancer].
    Kameoka H; Katayose K; Kumakawa K; Shiraiwa Y; Uchida H; Takahashi Y; Yazaki J; Yamaguchi O
    Gan To Kagaku Ryoho; 2005 Jan; 32(1):57-63. PubMed ID: 15675583
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CAG polymorphic repeat length in androgen receptor gene combined with pretreatment serum testosterone level as prognostic factor in patients with metastatic prostate cancer.
    Shimbo M; Suzuki H; Kamiya N; Imamoto T; Komiya A; Ueda T; Watanabe M; Shiraishi T; Ichikawa T
    Eur Urol; 2005 Apr; 47(4):557-63. PubMed ID: 15774258
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Complete androgen ablation suppresses prostate stem cell antigen (PSCA) mRNA expression in human prostate carcinoma.
    Zhigang Z; Wenlu S
    Prostate; 2005 Dec; 65(4):299-305. PubMed ID: 16015594
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of canine basal cells in prostatic post natal development, induction of hyperplasia, sex hormone-stimulated growth; and the ductal origin of carcinoma.
    Leav I; Schelling KH; Adams JY; Merk FB; Alroy J
    Prostate; 2001 May; 47(3):149-63. PubMed ID: 11351344
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prostate stem cell antigen (PSCA) expression in human prostate cancer tissues: implications for prostate carcinogenesis and progression of prostate cancer.
    Zhigang Z; Wenlv S
    Jpn J Clin Oncol; 2004 Jul; 34(7):414-9. PubMed ID: 15342669
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Elevated serum progastrin-releasing peptide (31-98) level is a predictor of short response duration after hormonal therapy in metastatic prostate cancer.
    Yashi M; Nukui A; Kurokawa S; Ochi M; Ishikawa S; Goto K; Kobayashi Y; Muraishi O; Tokue A
    Prostate; 2003 Sep; 56(4):305-12. PubMed ID: 12858359
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Radical prostatectomy and adjuvant endocrine therapy for prostate cancer with or without preoperative androgen deprivation: Five-year results.
    Homma Y; Akaza H; Okada K; Yokoyama M; Moriyama N; Usami M; Hirao Y; Tsushima T; Sakamoto A; Ohashi Y; Aso Y;
    Int J Urol; 2004 May; 11(5):295-303. PubMed ID: 15147545
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.
    Martinez AA; Demanes DJ; Galalae R; Vargas C; Bertermann H; Rodriguez R; Gustafson G; Altieri G; Gonzalez J
    Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1322-31. PubMed ID: 16029788
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of canine basal cells in postnatal prostatic development, induction of hyperplasia, and sex hormone-stimulated growth; and the ductal origin of carcinoma.
    Leav I; Schelling KH; Adams JY; Merk FB; Alroy J
    Prostate; 2001 Aug; 48(3):210-24. PubMed ID: 11494337
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Androgen receptor expression in clinically localized prostate cancer: immunohistochemistry study and literature review.
    Qiu YQ; Leuschner I; Braun PM
    Asian J Androl; 2008 Nov; 10(6):855-63. PubMed ID: 18958349
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Associations of serum testosterone with microvessel density, androgen receptor density and androgen receptor gene polymorphism in prostate cancer.
    Schatzl G; Madersbacher S; Haitel A; Gsur A; Preyer M; Haidinger G; Gassner C; Ochsner M; Marberger M
    J Urol; 2003 Apr; 169(4):1312-5. PubMed ID: 12629350
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Androgen receptor gene amplification at primary progression predicts response to combined androgen blockade as second line therapy for advanced prostate cancer.
    Palmberg C; Koivisto P; Kakkola L; Tammela TL; Kallioniemi OP; Visakorpi T
    J Urol; 2000 Dec; 164(6):1992-5. PubMed ID: 11061898
    [TBL] [Abstract][Full Text] [Related]  

  • 35. What pretreatment prostate-specific antigen level warrants long-term androgen deprivation?
    Feigenberg SJ; Hanlon AL; Horwitz EM; Uzzo RG; Eisenberg DF; Pollack A
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):1003-10. PubMed ID: 15752879
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression of insulin-like growth factor-1 receptor in local and metastatic prostate cancer.
    Ryan CJ; Haqq CM; Simko J; Nonaka DF; Chan JM; Weinberg V; Small EJ; Goldfine ID
    Urol Oncol; 2007; 25(2):134-40. PubMed ID: 17349528
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A comprehensive and novel predictive modeling technique using detailed pathology factors in men with localized prostate carcinoma.
    Potters L; Purrazzella R; Brustein S; Fearn P; Leibel SA; Kattan MW
    Cancer; 2002 Oct; 95(7):1451-6. PubMed ID: 12237913
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The independent impact of extended pattern biopsy on prostate cancer stage migration.
    Master VA; Chi T; Simko JP; Weinberg V; Carroll PR
    J Urol; 2005 Nov; 174(5):1789-93; discussion 1793. PubMed ID: 16217288
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prostate specific antigen half-time and prostate specific antigen doubling time as predictors of response to androgen deprivation therapy for metastatic prostate cancer.
    Park YH; Hwang IS; Jeong CW; Kim HH; Lee SE; Kwak C
    J Urol; 2009 Jun; 181(6):2520-4; discussion 2525. PubMed ID: 19371894
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data.
    Teh BS; Ayala G; Aguilar L; Mai WY; Timme TL; Vlachaki MT; Miles B; Kadmon D; Wheeler T; Caillouet J; Davis M; Carpenter LS; Lu HH; Chiu JK; Woo SY; Thompson T; Aguilar-Cordova E; Butler EB
    Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1520-9. PubMed ID: 15050332
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.